Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

7.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.0K
Therapeutic Communication01:30

Therapeutic Communication

8.8K
Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.8K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.0K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Patient Awareness of Sun Exposure and Eyelid Cancer.

Cureus·2026
Same author

Benign, irregularly shaped shoulder mass in a pediatric patient: A case report.

SAGE open medical case reports·2026
Same author

Outpatient Cutaneous Wound Care in the United States: Specialty Distribution and Antimicrobial Prescribing Patterns.

Antibiotics (Basel, Switzerland)·2026
Same author

Amphetamine Use is Common in Patients with Delusional Infestation.

Journal of cutaneous medicine and surgery·2026
Same author

Garadacimab-gxii-A Novel Prophylactic Treatment for Hereditary Angioedema: A Drug Review.

The Annals of pharmacotherapy·2026
Same author

The Characterization of the Relationship Between Field Cancerization and Number of Actinic Keratoses.

Journal of cutaneous medicine and surgery·2025

Related Experiment Video

Updated: Feb 15, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K

Insights into future therapeutics for atopic dermatitis.

Taylor Edwards1, Nupur U Patel1, Amy Blake1

  • 1a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Expert Opinion on Pharmacotherapy
|January 30, 2018
PubMed
Summary

Novel targeted therapies for atopic dermatitis (AD) are advancing through clinical trials. This review examines small molecule and other agents in phase II and III, offering hope for improved AD treatment algorithms.

Keywords:
Small molecule therapyatopic dermatitisclinical trialseczemafuture therapeuticsoral treatmenttopical treatment

More Related Videos

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

3.5K

Related Experiment Videos

Last Updated: Feb 15, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

3.5K

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Trials

Background:

  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition.
  • Current treatment options for AD are diverse, with ongoing research into novel therapeutic agents.

Purpose of the Study:

  • To review small molecule therapies and novel agents for atopic dermatitis in clinical development.
  • Focus on therapies in phase II and III clinical trials.

Main Methods:

  • Literature search of PubMed and ClinicalTrials.gov.
  • Compilation and assessment of clinical trial evidence for novel AD agents.

Main Results:

  • Multiple novel topical and oral therapies targeting AD pathogenesis are under investigation.
  • Agents include phosphodiesterase-4 inhibitors, boron molecules, Janus kinase inhibitors, and cannabinoid/kappa-opioid receptor agonists.
  • Compounds with unknown mechanisms of action are also being studied.

Conclusions:

  • Further clinical trials are necessary to fully understand these targeted therapies for AD.
  • Successful development of targeted therapies for AD is anticipated, given their efficacy in other inflammatory diseases.